2-GEP test rules out melanoma in real-world study

The noninvasive 2-gene expression profiling assay test has the ability to rule out melanoma with a negative predictive value over 99%, according to a real-world study presented at the Winter Clinical Conference.
“The 2-[gene expression profiling (GEP)] assay (DermTech) uses RT-qPCR to detect the gene expression of PRAME and LINC00518 RNA, two biomarkers that are common in melanomas but uncommon in their benign simulators, extracted from skin cells collected with noninvasive adhesive patches,” Laura Korb Ferris, MD, PhD, professor of dermatology at the University of Pittsburgh

The noninvasive 2-gene expression profiling assay test has the ability to rule out melanoma with a negative predictive value over 99%, according to a real-world study presented at the Winter Clinical Conference.
“The 2-[gene expression profiling (GEP)] assay (DermTech) uses RT-qPCR to detect the gene expression of PRAME and LINC00518 RNA, two biomarkers that are common in melanomas but uncommon in their benign simulators, extracted from skin cells collected with noninvasive adhesive patches,” Laura Korb Ferris, MD, PhD, professor of dermatology at the University of Pittsburgh